NCT01543906View on ClinicalTrials.gov

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Retinitis Pigmentosa (RP)
Interventions
DRUG

QLT091001

oral QLT091001 administered once daily for 7 days

Trial Locations (2)

Unknown

Montreal Children's Hospital, McGill University Health Centre, Montreal

Royal Victoria Eye and Ear Hospital, Dublin

All Listed Sponsors
lead

QLT Inc.

INDUSTRY

NCT01543906 - Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) | Biotech Hunter | Biotech Hunter